Ebinç H, Ozkurt Z N, Ebinç F A, Ucardag D, Caglayan O, Yilmaz M
Department of Cardiology, School of Medicine, University of Kirikkale, Kirikkale, Turkey.
J Int Med Res. 2008 Jan-Feb;36(1):80-7. doi: 10.1177/147323000803600111.
We examined whether moxonidine influences lipid profile, insulin resistance, adiponectin levels, renal function and microalbuminuria in women with essential hypertension in a study of 55 non-diabetic hypertensive patients and 53 normotensive women. Hypertensive patients received moxonidine for 12 weeks. At baseline the hypertensive group had significantly higher mean blood pressure, low-density lipoprotein cholesterol, triglycerides, total cholesterol, fasting glucose, urinary albumin excretion and homeostasis model assessment of insulin resistance (HOMA-IR), together with significantly lower mean high-density lipoprotein cholesterol, creatinine clearance and serum adiponectin than the normotensive group. Moxonidine significantly decreased blood pressure, fasting glucose, triglycerides, total cholesterol, HOMA-IR and albumin excretion, but significantly increased serum adiponectin. The change in adiponectin level was negatively correlated with the change in HOMA-IR. Moxonidine treatment may improve unfavourable metabolic status related to insulin resistance by increasing adiponectin levels in patients with essential hypertension. Since it can improve adiponectin levels, it may be used in the antihypertensive treatment of patients at high risk of diabetes and cardiovascular disease.
在一项针对55名非糖尿病高血压患者和53名血压正常女性的研究中，我们研究了莫索尼定对原发性高血压女性的血脂谱、胰岛素抵抗、脂联素水平、肾功能和微量白蛋白尿的影响。高血压患者接受莫索尼定治疗12周。在基线时，高血压组的平均血压、低密度脂蛋白胆固醇、甘油三酯、总胆固醇、空腹血糖、尿白蛋白排泄和胰岛素抵抗的稳态模型评估（HOMA-IR）显著高于血压正常组，而平均高密度脂蛋白胆固醇、肌酐清除率和血清脂联素则显著低于血压正常组。莫索尼定显著降低了血压、空腹血糖、甘油三酯、总胆固醇、HOMA-IR和白蛋白排泄，但显著提高了血清脂联素。脂联素水平的变化与HOMA-IR的变化呈负相关。莫索尼定治疗可能通过提高原发性高血压患者的脂联素水平来改善与胰岛素抵抗相关的不良代谢状态。由于它可以提高脂联素水平，因此可用于糖尿病和心血管疾病高危患者的降压治疗。
